Low Vaccination Rates Force Governments to Cancel H1N1 Flu Vaccine Orders
Just a few month ago a forecast made by analysts of Market Research Media Ltd seemed to undermine impact of the H1N1 pandemic on the vaccine market - according to this market research report “Global Pandemic Influenza Preparedness Market Forecast 2010-2015” the worldwide government spending on Pandemic Influenza Preparedness would grow at rather moderate rate [...]
Influenza Vaccine Adjuvant to Improve Effectiveness of Flu Vaccine for Elders
Juvaris BioTherapeutics, Inc., a biotech company developing adjuvanted vaccines for infectious diseases, has begun enrolling patients in a Phase 2 clinical trial of JVRS-100, an adjuvant for seasonal influenza vaccines in the elderly population. Seasonal influenza affects approximately one billion people worldwide each year resulting in 5 million severe illnesses and 500,000 deaths. Approximately 90 [...]
New Joint Venture To Build Asia’s Largest Influenza Vaccine Facility
Microbix, (TSX:MBX) a Canadian developer of a patented technology that increases influenza vaccine yields, has signed a joint venture agreement with the Hunan Biopharmaceutical Co. Ltd. (a Chinese Hunan Province state-owned enterprise) for initial financing to build Asia’s largest influenza vaccine production facility and the third largest vaccine plant in the world. A newly formed [...]
DNA Vaccine Potential
Inovio has created a novel platform for developing and delivering “universal” DNA-based vaccines against diseases such as influenza, HIV, malaria, dengue, and cervical cancer. Inovio’s universal vaccines have shown preclinical results indicating their potential to protect against new, unknown strains of an infectious disease such as the currently circulating H1N1 “swine flu.”
Dr. J. Joseph [...]
U.S. Government Funds Vaccine Adjuvant Development
U.S. government, through the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded six new research contracts to discover and characterize novel adjuvants, substances that can be added to vaccines to enhance the protective immune response they induce.
Global Pandemic Influenza Preparedness Market Forecast 2010-2015
Currently, the [...]
Vaccines Conference in Boston, September 23 - 25, 2009
The Vaccines Development Conference brings together scientists and industry experts in all aspects of vaccine development to share what’s working and not working for them, and to address your key vaccine development challenges and questions. The conference is held Boston, September 23 - 25, 2009.
Conference highlights:
Novel Adjuvant Development: Hear current advances in novel [...]
Cancer Vaccine: Vical Presents Positive Preclinical Results
Vical Incorporated presents encouraging results from animal studies of a peptide-based cancer vaccine formulated with the company’s Vaxfectin(R) adjuvant. Sean M. Sullivan, Ph.D., Vical’s Executive Director of Pharmaceutical Sciences, is presenting data at the IIRUSA Vaccines Development Forum (Boston - September 23-25) demonstrating the adjuvant’s ability to enhance immune responses of cancer antigen-based vaccines in [...]
HIV Vaccine: GenVec Receives Federal Funding
GenVec will receive up to $2.3 million for the 4th year to support the generation of HIV vaccine candidates with GenVec’s alternate adenovirus serotype technology. The National Institute of Allergy and Infectious Disease (NIAID) has executed its third option period (year four) under a previously announced, five-year contract with GenVec valued at up to $52 [...]
World Vaccine Congress Lyon 2009
World Vaccine Congress Lyon 2009, a Europe’s leading vaccine conference, will be held on October 5-8, 2009 in Lyon, France. The World Vaccine Congress Lyon is the annual vaccine conference addressing every aspect of vaccine research, vaccine development and vaccine manufacturing.
Highlights:
Representation from key European Commission and regulatory agencies
DG Research, DG SANCO, ECDC, EDQM, CHMP, VWP, [...]
Broad U.S. Patent Issued for Vaxfectin(R)-Formulated DNA Vaccines for Influenza
Vical Incorporated receives U.S. Patent No. 7,582,613 covering Vaxfectin(R)-formulated DNA vaccines for influenza. The patent provides broad coverage for any circulating or potential influenza viruses, including both seasonal and pandemic strains.
The company is currently developing Vaxfectin(R)-formulated DNA vaccines for both H5N1 avian-origin and H1N1 swine-origin pandemic influenza. Both vaccines are formulated with the company’s [...]
